Products Categories
CAS No.: | 40828-46-4 |
---|---|
Name: | Dolasteron |
Article Data: | 12 |
Molecular Structure: | |
Formula: | C14H12O3S |
Molecular Weight: | 260.313 |
Synonyms: | (?à)-Suprofen;2-[4-(Thiophene-2-carbonyl)phenyl]propanoic acid;Masterfen;NSC 303611;Profenal;Profenol;R 25061;Racemic suprofen;Srendam;Sulproltin;Supranol;Suprocil;Suprol;Sutoprofen;TN 762;p-(2-Thenoyl)hydratropic acid; |
EINECS: | 255-096-9 |
Density: | 1.29 g/cm3 |
Melting Point: | 278 °C |
Boiling Point: | 442.598 °C at 760 mmHg |
Flash Point: | 221.475 °C |
Solubility: | soluble in water |
Transport Information: | UN 3249 |
PSA: | 82.61000 |
LogP: | 3.16720 |
MF: C14H12O3S
MW: 260.30828
EINECS: 255-096
Density: 1.29 g/cm3
Flash Point: 221.5 °C
Melting Point: 278°C
Water Solubility: soluble
Index of Refraction: 1.612
Enthalpy of Vaporization: 73.79 kJ/mol
Boiling Point: 442.6 °C at 760 mmHg
Vapour Pressure: 1.3E-08 mmHg at 25°C
Stability: Stable at normal temperatures and pressures.
IUPAC Name: 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
Chemical Properties P-(2-thenoyl)-hydratropicaci (40828-46-4): Off-White to Light-Brown
Synonyms: Dolasetron ; (+-)-2-(P-(2-thenoyl)phenyl)propionicacid ; Alpha-Methyl-4-(2-thienylcarbonyl)-benzeneaceticaci ; Alpha-methyl-4-(2-thienylcarbonyl)benzeneaceticacid ; Maldocil ; P-(2-thenoyl)-hydratropicaci ; P-(2-thenoyl)hydratropicacid ; R25061
Product Categories: Heterocyclic Compounds ; Heterocycles ; Intermediates & Fine Chemicals ; Pharmaceuticals
Following is the molecular structure of P-(2-thenoyl)-hydratropicaci (40828-46-4):
Usage of P-(2-thenoyl)-hydratropicaci (40828-46-4): Prostaglandin biosynthesis inhibitor. Analgesic;Bridged pseudopelletierine derivative; specific serotonin (5HT3) receptor antagonist. Antiemetic.
1. | skn-rbt 150 mg/30D-I MLD | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 15 (1987),3611. | ||
2. | orl-man TDLo:8571 µg/kg/4D-I:KID | DICPBB Drug Intelligence and Clinical Pharmacy. 20 (1986),860. | ||
3. | orl-man TDLo:2857 µg/kg:KID | AIMEAS Annals of Internal Medicine. 105 (1986),799. | ||
4. | orl-wmn TDLo:4 mg/kg:KID | AIMEAS Annals of Internal Medicine. 106 (1987),235. | ||
5. | orl-rat LD50:70,600 µg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 25 (1975),1526. | ||
6. | ipr-rat LD50:335 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),1005. | ||
7. | scu-rat LD50:500 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),1005. | ||
8. | orl-mus LD50:590 mg/kg | DRFUD4 Drugs of the Future. 1 (1976),148. | ||
9. | ipr-mus LD50:375 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),1005. | ||
10. | scu-mus LD50:710 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),1005. | ||
Poison by ingestion and intraperitoneal routes. Moderately toxic by subcutaneous route. Human systemic effects: changes in kidney tubules, hematuria. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of SOx. Used as an analgesic and anti-inflammatory agent.